Biologics And Small Molecule Targeted Therapies For Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, And Hidradenitis Suppurativa In The US: A Narrative Review

This narrative review examines the use of biologics and small molecule targeted therapies for pediatric dermatological conditions such as alopecia areata (AA), psoriasis, atopic dermatitis (AD), and hidradenitis suppurativa (HS) in the US. It highlights the FDA approval of ritlecitinib for pediatric AA, with baricitinib and upadacitinib in phase 3 trials. For psoriasis, drugs like secukinumab and ustekinumab are approved, while others are in trials. Pediatric AD treatments include dupilumab and upadacitinib. Adalimumab is approved for HS. These therapies offer improved efficacy and safety over traditional treatments, with ongoing trials potentially enhancing treatment guidelines and outcomes for pediatric patients.